Figure 5.

miDnm1a Treatment Improves Metabolic Cellular Activity at PND 18 until PND 30

(A) Aberrant NPY expression was observed in the hippocampus and specifically in the CA3 of control-injected Dnm1^Ftfl/Ftfl mice at PND 18; treatment with miDnm1a reverted this phenotype (p = 0.0012). Treated Dnm1^Ftfl/Ftfl mice did not differ from treated and control-injected Dnm1^+/+ mice (p > 0.05). (B) NPY expression varied among treated Dnm1^Ftfl/Ftfl mice at PND 30. However, treated Dnm1^Ftfl/Ftfl mice trended toward significance compared to treated Dnm1^+/+ mice (p = 0.057) and control-injected Dnm1^+/+ mice (p = 0.074). (C) At PND18 c-Fos staining showed increased neuronal activation in the hippocampal CA3 of control-injected Dnm1^Ftfl/Ftfl mice, which was significantly diminished in treated Dnm1^Ftfl/Ftfl mice (p < 0.00001). Treated Dnm1^Ftfl/Ftfl mice did not differ from Dnm1^+/+ controls (p > 0.05). (D) By PND 30, there was a modest increase in neuronal activation in the hippocampus, specifically in the CA3 region, of treated Dnm1^Ftfl/Ftfl mice compared to Dnm1^+/+controls, but this increase was not significant (p > 0.05). All images (A–D) were taken at 10× magnification. Scale bar of entire hippocampus represents 200 μm and ROI scale bar represents 20 μm. Analyses were executed using the Poisson overdispersion option in the GMLJ module of Jamovi’s software. 3–5 mice were used in these analysis, and data are reported as mean ± SEM. ^∗∗p < 0.01; ^∗∗∗p < 0.0001. See also Figure S3.